This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
by Zacks Equity Research
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.
Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates for both earnings and sales in the third quarter. The company maintains its guidance for operating expenses.
BMY vs. AZN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO
by Zacks Equity Research
Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.
Merck (MRK) Beats on Q3 Earnings, Lags Sales, Ups EPS View
by Zacks Equity Research
Merck (MRK) beat estimates for earnings while missing the same for sales in third-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
Agios Rides on Tibsovo Approval Amid Reliance on Celgene
by Zacks Equity Research
Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.
QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to expand test menu; latest European launch to boost portfolio and top line.
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well.
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke
Merck's Keytruda on a Roll in a Thriving Anti-PD-L1 Market
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Top Analyst Reports for AstraZeneca, Salesforce & Mastercard
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca (AZN), salesforce.com (CRM) and Mastercard (MA)
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
3 Large-Cap Pharma Stocks Performing Better Than Industry
by Zacks Equity Research
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
by Zacks Equity Research
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
by Zacks Equity Research
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Top Research Reports for JPMorgan, American Express & FedEx
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), American Express (AXP) and FedEx (FDX).
5 Reasons Why Investors Should Bet on Merck (MRK) Stock
by Zacks Equity Research
Here are some reasons why investors may consider putting their money into Merck (MRK) stock.
Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data
by Zacks Equity Research
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
Lilly's Novel Diabetes Candidate Shows Promise in Phase II
by Zacks Equity Research
Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.
Dow 30 Stock Roundup: Boeing Wins $9.2B Pilot Training Deal, Intel Keeps '18 View
by Swarup Gupta
The index advanced strongly this week before suffering a sharp decline on Thursday.
Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC
by Zacks Equity Research
Clovis' (CLVS) cancer drug, Rubraca, gets Breakthrough Therapy designation from the FDA for treating metastatic castration resistant prostate cancer with BRCA mutation.
QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to expand test menu; latest FDA approval to boost portfolio.
Roche Gets FDA Approval for New Formulation of Asthma Drug
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.